Workflow
破发股海正生材股东拟减持 2022年上市募8.45亿元

Group 1 - The core point of the news is that Sinopec Capital plans to reduce its stake in Haizheng Biomaterials by selling up to 2,026,700 shares, which represents no more than 1% of the total share capital, due to funding needs for business development [1] - As of the announcement date, Sinopec Capital holds 12,814,894 shares in Haizheng Biomaterials, accounting for 6.32% of the total share capital [1] - The estimated amount from the planned reduction is approximately 29.29 million yuan, based on the last trading price of 14.45 yuan per share [1] Group 2 - Sinopec Capital initially held 15,686,300 shares, representing 7.74% of the total share capital, and has cumulatively reduced its holdings by 2,871,400 shares, realizing approximately 32.23 million yuan [2] - The average reduction price during the previous transactions was 11.61 yuan per share for 980,580 shares, and 11.06 yuan per share for 2,026,800 shares [3] - Haizheng Biomaterials was listed on the STAR Market on August 16, 2022, with an initial issuance of 50,669,517 shares at a price of 16.68 yuan per share, but the stock is currently trading below its initial offering price [3][4] Group 3 - The total amount raised from the initial public offering (IPO) was 845.17 million yuan, with a net amount of 750.86 million yuan after deducting issuance costs, which was 575.02 million yuan less than the planned amount of 1.32588 billion yuan [4] - The funds raised are intended for a 150,000-ton polylactic acid project and the construction of a research and development center [4]